Kyverna Therapeutics, Inc. Interest Expense Nonoperating
Kyverna Therapeutics, Inc. (KYTX) reported Interest Expense Nonoperating of $674.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Kyverna Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $674.00K, a 4714.29% increase year-over-year.
- Kyverna Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $667.00K, a 2568.00% increase year-over-year.
- Kyverna Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $444.00K, a 1544.44% increase year-over-year.
- Kyverna Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $7.00K, a 78.13% decline year-over-year.
- Kyverna Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $489.00K, a 244.37% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $142.00K, a 24.06% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $187.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $674.00K 10-Q · filed 2026-08-11 | $1.34M 10-Q · filed 2026-08-11 | $1.78M derived: sum of 3 quarters · filed 2026-08-11 | $1.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $667.00K 10-Q · filed 2026-05-12 | $1.11M derived: sum of 2 quarters · filed 2026-05-12 | $1.12M derived: sum of 3 quarters · filed 2026-05-12 | $1.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $451.00K derived: sum of 2 quarters · filed 2026-03-26 | $465.00K derived: sum of 3 quarters · filed 2026-08-11 | $489.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $7.00K 10-Q · filed 2025-11-12 | $21.00K derived: sum of 2 quarters · filed 2026-08-11 | $45.00K 10-Q · filed 2025-11-12 | $73.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $14.00K 10-Q · filed 2026-08-11 | $38.00K 10-Q · filed 2026-08-11 | $66.00K derived: sum of 3 quarters · filed 2026-08-11 | $98.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $25.00K 10-Q · filed 2026-05-12 | $52.00K derived: sum of 2 quarters · filed 2026-05-12 | $84.00K derived: sum of 3 quarters · filed 2026-05-12 | $123.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $59.00K derived: sum of 2 quarters · filed 2026-03-26 | $98.00K derived: sum of 3 quarters · filed 2026-03-26 | $142.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-12 | $71.00K derived: sum of 2 quarters · filed 2025-11-12 | $115.00K 10-Q · filed 2025-11-12 | $162.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $39.00K 10-Q · filed 2025-08-12 | $83.00K 10-Q · filed 2025-08-12 | $130.00K derived: sum of 3 quarters · filed 2025-08-12 | $180.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $44.00K 10-Q · filed 2025-05-13 | $91.00K derived: sum of 2 quarters · filed 2025-05-13 | $141.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $97.00K derived: sum of 2 quarters · filed 2025-03-27 | $187.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $50.00K 10-Q · filed 2024-11-13 | $140.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |